InvestSMART

4DMedical Limited (ASX:4DX)

ALERT: Price-sensitive ASX Announcement for 4DX
Current share price for 4DX : $4.310 0.98 (29.43%)+
Announcement
Release
31 Jul 2026 10:13AM
Price at Release
$3.330
Full Release
download
Summary
4DMedical Limited has released its Quarterly Activity Report and Appendix 4C for the quarter ending 30 June 2026. The report highlights significant progress for the CT:VQ™ product, which has entered the U.S. outpatient market through a commercial agreement with SimonMed Imaging. The company's operating revenue for FY26 increased to $7.2 million, reflecting a 23% growth driven by increased scan volumes. The company now delivers SaaS products across 540 global sites, achieving a record 105,970 scans in Q4 FY26. 4DMedical maintains a strong cash balance of $278 million. Regulatory milestones include the TGA approval of CT:VQ™ and its commercial rollout in Australia. The company is preparing for Medicare reimbursement and has completed the acquisition of contextflow, enhancing its European operations. 4DMedical also secured a contract with GlaxoSmithKline and pursued strategic investments to expand its reach in the lung imaging market.
Key Points
  • CT:VQ™ entered U.S. outpatient market through SimonMed Imaging
  • FY26 operating revenue was $7.2 million, up 23%
  • 4DMedical delivers SaaS products at 540 sites globally
  • Recorded 105,970 scans in Q4 FY26
  • Cash balance as of 30 June 2026 was $278 million
  • TGA approval and commercial rollout of CT:VQ™ in Australia
  • Acquisition of contextflow completed, enhancing European operations
  • Contract with GlaxoSmithKline to support pulmonary drug development
  • Strategic investments to expand lung imaging market reach
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.